DK2650366T3 - Rationelt konstruerede meganucleaser med ændret sekvensspecificitet og DNA-bindingsaffinitet - Google Patents
Rationelt konstruerede meganucleaser med ændret sekvensspecificitet og DNA-bindingsaffinitet Download PDFInfo
- Publication number
- DK2650366T3 DK2650366T3 DK13164585.5T DK13164585T DK2650366T3 DK 2650366 T3 DK2650366 T3 DK 2650366T3 DK 13164585 T DK13164585 T DK 13164585T DK 2650366 T3 DK2650366 T3 DK 2650366T3
- Authority
- DK
- Denmark
- Prior art keywords
- sequence
- meganuclease
- dna
- cell
- seq
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/22—Ribonucleases RNAses, DNAses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
- C12N15/8201—Methods for introducing genetic material into plant cells, e.g. DNA, RNA, stable or transient incorporation, tissue culture methods adapted for transformation
- C12N15/8213—Targeted insertion of genes into the plant genome by homologous recombination
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/90—Stable introduction of foreign DNA into chromosome
- C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/90—Stable introduction of foreign DNA into chromosome
- C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
- C12N15/905—Stable introduction of foreign DNA into chromosome using homologous recombination in yeast
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/90—Stable introduction of foreign DNA into chromosome
- C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
- C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Mycology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Cell Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Virology (AREA)
- Obesity (AREA)
- Enzymes And Modification Thereof (AREA)
Claims (14)
1
1. Fremgangsmåde tsi at spaite en dobbeitstrenget DNA~ måigenkendelsessekvens i en eukaryot celle, hvilken fremgangsmåde omfatter: at indføre i den nævnte eukaryote celle 5 en nucleinsyre, der koder en meganuciease; eller et meganucleaseprotein; hvilken nævnte meganuciease spalter den nævnte dobbeltstrengede DNA-målgenkendelsessekvens; og hvilken meganucleasen er en rekombinant meganuciease, der omfatter: 10 et polypeptid, der har mindst 85 % sekvenslighed med grupperne 2-153 af l-Crel-meganucleasen med SEQ ID NO: 1; og som har en specificitet for et genkendelsessekvens-halv-site, der afviger med mindst ét basepar fra et halv-sste inden en l-Grel· meganuciease genkendelsessekvens, som er valgt fra gruppen beståen-15 de af SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4 og SEQ ID NO: 5, hvilken specificitet i position -1 er blevet ændret: (i) til et A ved en modifikation, der er valgt fra gruppen bestående af D75C, D75L, D75Y, K139Y, T46A, og T46C; (ii) til et G ved en modifikation, der er valgt fra gruppen bestående af 20 T46E, T46D, og D75E; eller (iii) til et T ved en modifikation, der er valgt fra gruppen bestående af D75H, D75Q, D75Y, K139H, T46H, og T46Q; (iv) til enhver base på en sensestreng ved en T46G modifikation; med det forbehold, at fremgangsmåden ikke er en fremgangsmåde til 25 behandling af en menneske- eller dyrekrop ved terapi; med det forbehold, at fremgangsmåden ikke er en fremgangsmåde til modificering af kønscellers genetiske identitet af mennesker og med det yderligere forbehold, at cellen ikke er en human embryonisk stamcelle eller human blastocyst-celle. 30
2. Fremgangsmåden ifølge krav 1, hvor den rekombinante meganuclease yderligere omfatter mindst en anden specificitet-ændrende aminosyresubstitution, der svarer til en substitution, som er valgt fra gruppen bestående af: I24C, I24K, I24R, Q28A, Q26E. Q26K, Q26S, K28A, K28C, K28H, K28Q, K28R, K28S, N30E, N30K, N30Q, N30R. S32A, S32C. S32D. S32E, S32H, S32I, S32K, S32L, S32N, S32Q, S32R, S32T, S32V, Y33C, Y33D, Y33E. Y33F, Y33H, Y33L Y33L, Y33R. Y33V, Q38C, Q38E. Q38H. Q38L Q38K, Q38L, Q38N. Q38R, S40A, S40C, S40E, S40I, S40Q, S40R, S40V, A42E, A42Q, A42R, Q44A, Q44C, Q44D. Q44E, Q44I, Q44K, Q44L, Q44N, Q44R, Q44T, Q44V, T46A, T46C, T46D. T46E, T46G, T46H, T46K, T46Q, T46R, Y66K, Y66M, R68C, R68E, R68F, R68H, R68K, R68L R68M, R68Q, R68Y, R70A, R70G, R70D, R70E, R70G, R70H, R70K, R7QL, R70Q, R70S. D75C, D75E, D75H. D75L D75G, D75R, D75Y, I77E, I77Q, I77R, I77S, S79A, S79G, S79S, S79V, K139H og K139Y.
3. Fremgangsmåde ifølge ethvert af de foregående krav, hvor den dobbeltstrengede DNA-målgenkendelsessekvens er omfattet i et kromosom i den eukaryote celle.
4. Fremgangsmåden ifølge krav 3, hvilken fremgangsmåde yderligere omfatter: at transfektere den nævnte eukaryote celle med en nucleinsyresekvens, der indbefatter en eksogen sekvens, hvilken nævnte exogene sekvens inserteres i kromosomet ved spaltningsstedet for derved at frembringe en genetisk modificeret eukaryot celle, der indbefatter den exogene sekvens, som inserteres i det nævnte kromosom af den nævnte eukaryote celle, eventuelt hvilken nævnte nucleinsyre yderligere omfatter sekvenser, der er homologe med sekvenser, som flankerer spaltningsstedet, og hvilken nævnte exogene sekvens inserteres ved det nævnte spaltningssted ved homolog rekombination, eller hvilken nucleinsyre mangler væsentlig homolog! med spaltningsstedet og den nævnte exogene sekvens inserteres i det nævnte kromosom ved ik-ke-homolog forbindelse af enderne.
5. Fremgangsmåden ifølge krav 3, hvor den nævnte målsekvens afbrydes ved ikke-homolog forbindelse af enderne på spaltningsstedet for derved at frembringe en genetisk modificeret eukaryot celle ved at afbryde målsekvensen i det nævnte kromosom af den nævnte eukaryote celle. β. Fremgangsmåde ifølge ethvert foregående krav, hvor den nævnte ceile er en plantecelle.
7. Fremgangsmåden ifølge krav 8, hvor den nævnte nucieinsyre indføres I den nævnte celle ved en Agrobacteriurn-vektor, ballistisk injektion, mikroprojektil-bombardement eller elektroporering,
8. Fremgangsmåden ifølge krav 6, hvor den nævnte celle er en protoplast og den nævnte nucieinsyre indføres i den nævnte celle ved PEG-medieret transformation.
9. Fremgangsmåde ifølge et hvilket som helst af kravene 1-5, hvor den nævnte celle er en pattedyrcelle.
10. Fremgangsmåden ifølge krav 9, hvor den nævnte nucieinsyre indføres i den nævnte celle ved en adenovirus, en adeno-associeret virusvektor, ballistisk injektion, elektroporation, mikroinjektion eiler liposomtransfektion.
11. Fremgangsmåde ifølge et hvilket som helst af kravene 1-5 eller 9-10, hvor cellen er valgt fra gruppen bestående af en gamet, en zygot, en blastocyst celle, en embryonisk stamcelle, og en protoplast-celle, med det forbehold, at fremgangsmåden ikke er en fremgangsmåde til behandling af en menneske- eller dyrekrop ved terapi; med det forbehold, at fremgangsmåden ikke er en fremgangsmåde til modificering af kønscellers genetiske identitet af mennesker og med det yderligere forbehold, at cellen ikke er en human embryonisk stamcelle eller human blastocyst celle.
12. Rekombinant meganuclease, der omfatter: et polypeptid, som har mindst 85 % sekvenslighed med grupperne 2-153 af l-Grel-meganucieasen med SEG ID NO: 1; og som har specificitet for et genkendelsessekvens-haiv-site, der afviger med mindst ét basepar fra et halv-site inden en l-Crel-meganudease-genkendelsessekvens, som er valgt fra gruppen bestående af SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4 og SEQ ID NO: 5, hvilken specificitet i position -1 er blevet ændret: (i) til et A ved en modifikation, der er valgt fra gruppen bestående af D75C, D75L, D75Y, K139Y, T46A, og T46C; (ii) til et G ved en modifikation, der er valgt fra gruppen bestående af T46E, T46D, og D75E; eller (iii) til et T ved en modifikation, der er valgt fra gruppen bestående af D75H, D75Q, D75Y, K139H, T48H, og T46Q; (iv) til enhver base på en sense-streng ved en T46G modifikation.
13. Rekombinant meganudease ifølge krav 12 til anvendelse i genterapi eller til behandling af patogene infektioner.
14. Anvendelse af den rekombinante meganudease ifølge krav 12 til fremstilling af et medikament til anvendelse i genterapi eller til behandling af patogene infektioner.
15. Anvendelse af den rekombinante meganudease ifølge krav 12 i in vitro applikationer i diagnostik og i forskning.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US72751205P | 2005-10-18 | 2005-10-18 | |
EP06826293.0A EP1945762B1 (en) | 2005-10-18 | 2006-10-18 | Rationally-designed meganucleases with altered sequence specificity and dna-binding affinity |
Publications (1)
Publication Number | Publication Date |
---|---|
DK2650366T3 true DK2650366T3 (da) | 2017-07-10 |
Family
ID=37963286
Family Applications (9)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK12162075.1T DK2484758T3 (da) | 2005-10-18 | 2006-10-18 | Rationelt konstruerede meganucleaser med ændret sekvensspecificitet og DNA-bindingsaffinitet |
DK13164623.4T DK2662442T3 (da) | 2005-10-18 | 2006-10-18 | Rationelt designet meganuklease med ændret dimerdannelsesaffinitet |
DK06826293.0T DK1945762T3 (da) | 2005-10-18 | 2006-10-18 | Rationelt konstruerede meganucleaser med ændret sekvensspecificitet og DNA-bindingsaffinitet |
DK10191904T DK2360244T3 (da) | 2005-10-18 | 2006-10-18 | Rationelt konstruerede meganukleaser med ændret specificitet og DNA-bindingsaffinitet |
DK13164585.5T DK2650366T3 (da) | 2005-10-18 | 2006-10-18 | Rationelt konstruerede meganucleaser med ændret sekvensspecificitet og DNA-bindingsaffinitet |
DK17161899.4T DK3246403T3 (da) | 2005-10-18 | 2006-10-18 | Rationelt designede meganucleaser med ændret sekvens-specificitet og dna-bindende affinitet |
DK10191888.6T DK2357226T3 (da) | 2005-10-18 | 2006-10-18 | Rationelt udformede meganukleaser med ændret sekvensspecificitet og DNA-bindingsaffinitet |
DK13164564.0T DK2650365T3 (da) | 2005-10-18 | 2006-10-18 | Rationelt konstruerede meganukleaser med ændret sekvensspecificitet og dna-bindingsaffinitet |
DK13164628.3T DK2628794T3 (da) | 2005-10-18 | 2006-10-18 | Rationelt konstruerede meganukleaser med ændret sekvensspecificitet og dna-bindingsaffinitet |
Family Applications Before (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK12162075.1T DK2484758T3 (da) | 2005-10-18 | 2006-10-18 | Rationelt konstruerede meganucleaser med ændret sekvensspecificitet og DNA-bindingsaffinitet |
DK13164623.4T DK2662442T3 (da) | 2005-10-18 | 2006-10-18 | Rationelt designet meganuklease med ændret dimerdannelsesaffinitet |
DK06826293.0T DK1945762T3 (da) | 2005-10-18 | 2006-10-18 | Rationelt konstruerede meganucleaser med ændret sekvensspecificitet og DNA-bindingsaffinitet |
DK10191904T DK2360244T3 (da) | 2005-10-18 | 2006-10-18 | Rationelt konstruerede meganukleaser med ændret specificitet og DNA-bindingsaffinitet |
Family Applications After (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK17161899.4T DK3246403T3 (da) | 2005-10-18 | 2006-10-18 | Rationelt designede meganucleaser med ændret sekvens-specificitet og dna-bindende affinitet |
DK10191888.6T DK2357226T3 (da) | 2005-10-18 | 2006-10-18 | Rationelt udformede meganukleaser med ændret sekvensspecificitet og DNA-bindingsaffinitet |
DK13164564.0T DK2650365T3 (da) | 2005-10-18 | 2006-10-18 | Rationelt konstruerede meganukleaser med ændret sekvensspecificitet og dna-bindingsaffinitet |
DK13164628.3T DK2628794T3 (da) | 2005-10-18 | 2006-10-18 | Rationelt konstruerede meganukleaser med ændret sekvensspecificitet og dna-bindingsaffinitet |
Country Status (9)
Country | Link |
---|---|
US (19) | US8021867B2 (da) |
EP (13) | EP2357226B1 (da) |
JP (9) | JP5937292B2 (da) |
AT (1) | ATE549401T1 (da) |
AU (1) | AU2006304668B2 (da) |
CA (3) | CA2626262C (da) |
DK (9) | DK2484758T3 (da) |
ES (9) | ES2533370T3 (da) |
WO (1) | WO2007047859A2 (da) |
Families Citing this family (434)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE60316124T3 (de) † | 2002-03-15 | 2018-03-22 | Cellectis | Hybride and einzelkettige meganukleasen und deren anwendungen |
WO2009095742A1 (en) | 2008-01-31 | 2009-08-06 | Cellectis | New i-crei derived single-chain meganuclease and uses thereof |
AU2004208031B2 (en) * | 2003-01-28 | 2009-10-08 | Cellectis | Use of meganucleases for inducing homologous recombination ex vivo and in toto in vertebrate somatic tissues and application thereof. |
US20110158974A1 (en) * | 2005-03-15 | 2011-06-30 | Cellectis | Heterodimeric Meganucleases and Use Thereof |
WO2007060495A1 (en) † | 2005-10-25 | 2007-05-31 | Cellectis | I-crei homing endonuclease variants having novel cleavage specificity and use thereof |
AU2007267874B2 (en) * | 2006-05-25 | 2012-03-15 | Sangamo Therapeutics, Inc. | Methods and compositions for gene inactivation |
WO2008093152A1 (en) * | 2007-02-01 | 2008-08-07 | Cellectis | Obligate heterodimer meganucleases and uses thereof |
WO2008102198A1 (en) * | 2007-02-19 | 2008-08-28 | Cellectis | Laglidadg homing endonuclease variants having novel substrate specificity and use thereof |
AU2008258782B2 (en) | 2007-06-05 | 2013-09-19 | Bayer Cropscience Ag | Methods and means for exact replacement of target DNA in eukaryotic organisms |
WO2009002425A2 (en) * | 2007-06-22 | 2008-12-31 | Scidose Llc | Solubilized formulation of docetaxel without tween 80 |
EP2568048A1 (en) * | 2007-06-29 | 2013-03-13 | Pioneer Hi-Bred International, Inc. | Methods for altering the genome of a monocot plant cell |
WO2009013559A1 (en) * | 2007-07-23 | 2009-01-29 | Cellectis | Meganuclease variants cleaving a dna target sequence from the human hemoglobin beta gene and uses thereof |
WO2009019528A1 (en) * | 2007-08-03 | 2009-02-12 | Cellectis | Meganuclease variants cleaving a dna target sequence from the human interleukin-2 receptor gamma chain gene and uses thereof |
US11235026B2 (en) | 2007-09-27 | 2022-02-01 | Sangamo Therapeutics, Inc. | Methods and compositions for modulating PD1 |
WO2009042163A2 (en) * | 2007-09-27 | 2009-04-02 | Sangamo Biosciences, Inc. | Rapid in vivo identification of biologically active nucleases |
US8563314B2 (en) | 2007-09-27 | 2013-10-22 | Sangamo Biosciences, Inc. | Methods and compositions for modulating PD1 |
DK2215223T3 (da) | 2007-10-31 | 2013-07-22 | Prec Biosciences Inc | Rationelt konstruerede enkeltkæde-meganucleaser med ikke-palindrome genkendelsessekvenser |
US20110041194A1 (en) * | 2007-11-28 | 2011-02-17 | Cellectis | I-msoi homing endonuclease variants having novel substrate specificity and use thereof |
JP2011505809A (ja) * | 2007-12-07 | 2011-03-03 | プレシジョン バイオサイエンシズ,インク. | ヒトゲノムのDNase高感受性領域に見出される認識配列を有する合理的に設計されたメガヌクレアーゼ |
MX341747B (es) | 2008-02-29 | 2016-08-31 | Monsanto Technology Llc | Evento de maiz mon87460 y composiciones y metodos para detectarlo. |
WO2009114321A2 (en) | 2008-03-11 | 2009-09-17 | Precision Biosciencs, Inc. | Rationally-designed meganucleases for maize genome engineering |
US20100071083A1 (en) * | 2008-03-12 | 2010-03-18 | Smith James J | Temperature-dependent meganuclease activity |
WO2009131632A1 (en) | 2008-04-14 | 2009-10-29 | Sangamo Biosciences, Inc. | Linear donor constructs for targeted integration |
CA2722797A1 (en) * | 2008-04-28 | 2009-11-05 | Precision Biosciences, Inc. | Fusion molecules of rationally-designed dna-binding proteins and effector domains |
CA2730921A1 (en) | 2008-07-14 | 2010-01-21 | Precision Biosciences, Inc. | Recognition sequences for i-crei-derived meganucleases and uses thereof |
CN102159722B (zh) | 2008-08-22 | 2014-09-03 | 桑格摩生物科学股份有限公司 | 用于靶向单链切割和靶向整合的方法和组合物 |
AU2009333863B2 (en) * | 2008-12-17 | 2015-02-05 | Corteva Agriscience Llc | Targeted integration into the Zp15 locus |
EP2393506B1 (en) | 2009-02-04 | 2018-03-28 | Sangamo Therapeutics, Inc. | Methods and compositions for treating neuropathies |
WO2010093966A2 (en) * | 2009-02-12 | 2010-08-19 | Fred Hutchinson Cancer Research Center | Generation of a dna nicking enzyme that stimulates site-specific gene conversion from a homing endonuclease |
AU2010226313B2 (en) | 2009-03-20 | 2014-10-09 | Sangamo Therapeutics, Inc. | Modification of CXCR4 using engineered zinc finger proteins |
WO2010122367A2 (en) * | 2009-04-21 | 2010-10-28 | Cellectis | Meganuclease variants cleaving the genomic insertion of a virus and uses thereof |
US8772008B2 (en) | 2009-05-18 | 2014-07-08 | Sangamo Biosciences, Inc. | Methods and compositions for increasing nuclease activity |
US20120171191A1 (en) * | 2009-05-26 | 2012-07-05 | Cellectis | Meganuclease variants cleaving the genome of a pathogenic non-integrating virus and uses thereof |
WO2010136841A2 (en) * | 2009-05-26 | 2010-12-02 | Cellectis | Meganuclease variants cleaving the genome of a non-genomically integrating virus and uses thereof |
EP2449135B1 (en) | 2009-06-30 | 2016-01-06 | Sangamo BioSciences, Inc. | Rapid screening of biologically active nucleases and isolation of nuclease-modified cells |
EP2461819A4 (en) | 2009-07-28 | 2013-07-31 | Sangamo Biosciences Inc | METHODS AND COMPOSITIONS FOR TREATING TRI-NUCLEOTIDE REPEAT DISORDERS |
NZ598457A (en) * | 2009-08-03 | 2014-06-27 | Recombinetics Inc | Methods and compositions for targeted gene modification |
US8586526B2 (en) | 2010-05-17 | 2013-11-19 | Sangamo Biosciences, Inc. | DNA-binding proteins and uses thereof |
KR102262704B1 (ko) | 2009-08-11 | 2021-06-09 | 상가모 테라퓨틱스, 인코포레이티드 | 표적화 변형에 대한 동형접합성 유기체 |
NZ599351A (en) | 2009-10-22 | 2014-02-28 | Dow Agrosciences Llc | Engineered zinc finger proteins targeting plant genes involved in fatty acid biosynthesis |
EP2319872A1 (en) | 2009-11-04 | 2011-05-11 | BASF Plant Science GmbH | Amylopectin type starch with enhanced retrogradation stability |
CN102725412B (zh) | 2009-11-27 | 2017-09-22 | 巴斯夫植物科学有限公司 | 优化的内切核酸酶及其用途 |
EP2504430A4 (en) | 2009-11-27 | 2013-06-05 | Basf Plant Science Co Gmbh | CHIMERIC ENDONUCLEASES AND USES THEREOF |
CA2781693C (en) | 2009-11-27 | 2018-12-18 | Basf Plant Science Company Gmbh | Chimeric endonucleases and uses thereof |
US8704041B2 (en) * | 2009-12-30 | 2014-04-22 | Pioneer Hi Bred International Inc | Methods and compositions for targeted polynucleotide modification |
US20110203012A1 (en) * | 2010-01-21 | 2011-08-18 | Dotson Stanton B | Methods and compositions for use of directed recombination in plant breeding |
WO2011100058A1 (en) | 2010-02-09 | 2011-08-18 | Sangamo Biosciences, Inc. | Targeted genomic modification with partially single-stranded donor molecules |
WO2011104382A1 (en) * | 2010-02-26 | 2011-09-01 | Cellectis | Use of endonucleases for inserting transgenes into safe harbor loci |
CN103025866A (zh) | 2010-03-22 | 2013-04-03 | 菲利普莫里斯生产公司 | 修饰植物中酶的活性 |
LT2566972T (lt) | 2010-05-03 | 2020-03-10 | Sangamo Therapeutics, Inc. | Kompozicijos, skirtos cinko pirštu modulių susiejimui |
US9574201B2 (en) * | 2010-06-09 | 2017-02-21 | Bayer Cropscience Nv | Methods and means to modify a plant genome at a nucleotide sequence commonly used in plant genome engineering |
AU2011264074B2 (en) * | 2010-06-09 | 2015-01-22 | Bayer Cropscience Nv | Methods and means to modify a plant genome at a nucleotide sequence commonly used in plant genome engineering |
EP2596011B1 (en) | 2010-07-21 | 2018-10-03 | Sangamo Therapeutics, Inc. | Methods and compositions for modification of a hla locus |
US20130164850A1 (en) * | 2010-08-02 | 2013-06-27 | David Sourdive | Method for targeted genomic events in algae |
EP3511420B1 (en) | 2010-09-27 | 2021-04-07 | Sangamo Therapeutics, Inc. | Compositions for inhibiting viral entry into cells |
US20140137292A1 (en) | 2011-01-14 | 2014-05-15 | University Of Florida Research Foundation Inc. | Citrus trees with resistance to citrus canker |
US10030245B2 (en) | 2011-03-23 | 2018-07-24 | E I Du Pont De Nemours And Company | Methods for producing a complex transgenic trait locus |
WO2012138901A1 (en) * | 2011-04-05 | 2012-10-11 | Cellectis Sa | Method for enhancing rare-cutting endonuclease efficiency and uses thereof |
US9476040B2 (en) | 2011-05-02 | 2016-10-25 | Board Of Regents Of The University Of Nebraska | Plants with useful traits and related methods |
EP2535416A1 (en) | 2011-05-24 | 2012-12-19 | BASF Plant Science Company GmbH | Development of phytophthora resistant potato with increased yield |
DK3489366T3 (da) | 2011-06-01 | 2020-02-24 | Prec Biosciences Inc | Fremgangsmåder og produkter til produktion af manipulerede mammale cellelinier med forstærkede transgener |
TR201802544T4 (tr) | 2011-06-06 | 2018-03-21 | Bayer Cropscience Nv | Önceden seçilmiş bir bölgede bir bitki genomunu modifiye için yöntemler ve araçlar. |
CN103620027B (zh) | 2011-06-10 | 2017-11-21 | 巴斯夫植物科学有限公司 | 核酸酶融合蛋白及其用途 |
AU2012333207A1 (en) | 2011-06-21 | 2014-01-23 | E.I. Du Pont De Nemours And Company | Methods and compositions for producing male sterile plants |
US20130097734A1 (en) | 2011-07-12 | 2013-04-18 | Two Blades Foundation | Late blight resistance genes |
JP6072788B2 (ja) | 2011-07-25 | 2017-02-01 | サンガモ バイオサイエンシーズ, インコーポレイテッド | 嚢胞性線維症膜コンダクタンス制御因子(cftr)遺伝子を改変するための方法および組成物 |
AU2013204310C1 (en) * | 2011-08-22 | 2015-12-10 | BASF Agricultural Solutions Seed US LLC | Methods and means to modify a plant genome |
BR112014003919A2 (pt) * | 2011-08-22 | 2017-03-14 | Bayer Cropscience Ag | métodos e meios para modificar um genoma de planta |
CA2848417C (en) | 2011-09-21 | 2023-05-02 | Sangamo Biosciences, Inc. | Methods and compositions for regulation of transgene expression |
AU2012328682B2 (en) | 2011-10-27 | 2017-09-21 | Sangamo Therapeutics, Inc. | Methods and compositions for modification of the HPRT locus |
EP2612918A1 (en) | 2012-01-06 | 2013-07-10 | BASF Plant Science Company GmbH | In planta recombination |
AU2013209738A1 (en) | 2012-01-17 | 2014-08-07 | Australian Center For Plant Functional Genomics, Pty, Ltd | Plant transcription factors, promoters and uses thereof |
BR112014018294B1 (pt) | 2012-01-26 | 2022-01-11 | Norfolk Plant Sciences, Ltd | Método para produzir uma planta, cassete de expressão, e, célula bacteriana |
AU2013225950B2 (en) | 2012-02-29 | 2018-02-15 | Sangamo Therapeutics, Inc. | Methods and compositions for treating huntington's disease |
HUP1400495A2 (en) | 2012-03-13 | 2015-03-02 | Univ Guelph Guelph Ontario | Methods of increasing tolerance to heat stress and amino acid content of plants |
WO2013136274A1 (en) | 2012-03-13 | 2013-09-19 | University Of Guelph | Myb55 promoter and use thereof |
EP2841581B2 (en) | 2012-04-23 | 2023-03-08 | BASF Agricultural Solutions Seed US LLC | Targeted genome engineering in plants |
JP6352250B2 (ja) | 2012-05-02 | 2018-07-04 | ダウ アグロサイエンシィズ エルエルシー | リンゴ酸デヒドロゲナーゼの標的改変 |
BR112014027468A2 (pt) | 2012-05-04 | 2017-06-27 | Du Pont | polinucleotídeo isolado ou recombinante, construção de dna recombinante, célula, planta, explante vegetal, semente transgênica, polipeptídeo isolado, composição, métodos de produção de meganuclease, de introdução de rompimento e de integração de um polinucleotídeo. |
AU2013259647B2 (en) | 2012-05-07 | 2018-11-08 | Corteva Agriscience Llc | Methods and compositions for nuclease-mediated targeted integration of transgenes |
ES2613691T3 (es) | 2012-07-11 | 2017-05-25 | Sangamo Biosciences, Inc. | Métodos y composiciones para el tratamiento de enfermedades por almacenamiento lisosomal |
JP6329537B2 (ja) | 2012-07-11 | 2018-05-23 | サンガモ セラピューティクス, インコーポレイテッド | 生物学的薬剤の送達のための方法および組成物 |
WO2014036219A2 (en) | 2012-08-29 | 2014-03-06 | Sangamo Biosciences, Inc. | Methods and compositions for treatment of a genetic condition |
EP3763810A3 (en) | 2012-10-10 | 2021-07-14 | Sangamo Therapeutics, Inc. | T cell modifying compounds and uses thereof |
MX361412B (es) | 2012-11-27 | 2018-12-05 | Childrens Medical Center | Direccion de elementos reguladores distales de bcl11a para reinduccion de hemoglobina fetal. |
BR102013032200A2 (pt) | 2012-12-13 | 2015-11-24 | Dow Agrosciences Llc | direcionamento preciso de um gene para um locus específico em milho |
CA2901676C (en) * | 2013-02-25 | 2023-08-22 | Sangamo Biosciences, Inc. | Methods and compositions for enhancing nuclease-mediated gene disruption |
US10240125B2 (en) | 2013-03-14 | 2019-03-26 | Immusoft Corporation | Methods for in vitro memory B cell differentiation and transduction with VSV-G pseudotyped viral vectors |
CA2908403A1 (en) | 2013-04-02 | 2014-10-09 | Bayer Cropscience Nv | Targeted genome engineering in eukaryotes |
CA2908512C (en) | 2013-04-05 | 2023-10-24 | Dow Agrosciences Llc | Methods and compositions for integration of an exogenous sequence within the genome of plants |
JP6443811B2 (ja) | 2013-07-10 | 2018-12-26 | エフストック リミテッド ライアビリティ カンパニー | Mrap2ノックアウト |
WO2015026887A1 (en) | 2013-08-22 | 2015-02-26 | E. I. Du Pont De Nemours And Company | A soybean u6 polymerase iii promoter and methods of use |
CA2920899C (en) | 2013-08-28 | 2023-02-28 | Sangamo Biosciences, Inc. | Compositions for linking dna-binding domains and cleavage domains |
US20160251410A1 (en) | 2013-09-03 | 2016-09-01 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Compositions and methods for expressing recombinant polypeptides |
US10767188B2 (en) | 2013-09-25 | 2020-09-08 | Nutech Ventures | Methods and compositions for obtaining useful plant traits |
KR20150037550A (ko) * | 2013-09-30 | 2015-04-08 | 주식회사 엘지화학 | 국지적으로 편광 해소 영역을 갖는 편광판 및 그 제조 방법 |
EP3057432B1 (en) | 2013-10-17 | 2018-11-21 | Sangamo Therapeutics, Inc. | Delivery methods and compositions for nuclease-mediated genome engineering in hematopoietic stem cells |
ES2881473T3 (es) | 2013-10-17 | 2021-11-29 | Sangamo Therapeutics Inc | Métodos de suministro y composiciones para la modificación por ingeniería genética del genoma mediada por nucleasas |
AU2014341929B2 (en) | 2013-11-04 | 2017-11-30 | Corteva Agriscience Llc | Optimal maize loci |
JP6560205B2 (ja) | 2013-11-04 | 2019-08-14 | ダウ アグロサイエンシィズ エルエルシー | 最適なダイズ遺伝子座 |
CN106164085A (zh) | 2013-11-04 | 2016-11-23 | 美国陶氏益农公司 | 最优玉米座位 |
KR102431079B1 (ko) | 2013-11-11 | 2022-08-11 | 상가모 테라퓨틱스, 인코포레이티드 | 헌팅턴병을 치료하기 위한 방법 및 조성물 |
WO2015073683A2 (en) | 2013-11-13 | 2015-05-21 | Children's Medical Center Corporation | Nuclease-mediated regulation of gene expression |
CA2931637C (en) | 2013-12-09 | 2023-10-10 | Sangamo Biosciences, Inc. | Methods and compositions for treating hemophilia |
CA2933707A1 (en) | 2013-12-20 | 2015-06-25 | Fred Hutchinson Cancer Research Center | Tagged chimeric effector molecules and receptors thereof |
WO2015116680A1 (en) | 2014-01-30 | 2015-08-06 | Two Blades Foundation | Plants with enhanced resistance to phytophthora |
WO2015117081A2 (en) | 2014-02-03 | 2015-08-06 | Sangamo Biosciences, Inc. | Methods and compositions for treatment of a beta thalessemia |
US10370680B2 (en) | 2014-02-24 | 2019-08-06 | Sangamo Therapeutics, Inc. | Method of treating factor IX deficiency using nuclease-mediated targeted integration |
TW201538518A (zh) | 2014-02-28 | 2015-10-16 | Dow Agrosciences Llc | 藉由嵌合基因調控元件所賦予之根部特異性表現 |
JP2017512767A (ja) | 2014-03-12 | 2017-05-25 | プレシジョン バイオサイエンシズ,インク. | 改変ヌクレアーゼを用いたジストロフィン遺伝子エクソンの欠失 |
CN106459894B (zh) | 2014-03-18 | 2020-02-18 | 桑格摩生物科学股份有限公司 | 用于调控锌指蛋白表达的方法和组合物 |
GB201407852D0 (en) | 2014-05-02 | 2014-06-18 | Iontas Ltd | Preparation of libraries od protein variants expressed in eukaryotic cells and use for selecting binding molecules |
WO2015171603A1 (en) | 2014-05-06 | 2015-11-12 | Two Blades Foundation | Methods for producing plants with enhanced resistance to oomycete pathogens |
RU2691102C2 (ru) | 2014-05-08 | 2019-06-11 | Сангамо Байосайенсиз, Инк. | Способы и композиции для лечения болезни хантингтона |
DE102014209264B8 (de) * | 2014-05-15 | 2017-01-12 | Olympus Winter & Ibe Gmbh | Hochfrequenz-Chirurgiegerät |
BR112016028023A2 (pt) * | 2014-05-30 | 2017-08-22 | Univ Leland Stanford Junior | Composições e métodos de administração de tratamentos para infecções virais latentes |
US10676754B2 (en) | 2014-07-11 | 2020-06-09 | E I Du Pont De Nemours And Company | Compositions and methods for producing plants resistant to glyphosate herbicide |
US9616090B2 (en) | 2014-07-30 | 2017-04-11 | Sangamo Biosciences, Inc. | Gene correction of SCID-related genes in hematopoietic stem and progenitor cells |
CA2960769A1 (en) | 2014-09-16 | 2016-03-24 | Sangamo Therapeutics, Inc. | Methods and compositions for nuclease-mediated genome engineering and correction in hematopoietic stem cells |
US11021718B2 (en) | 2014-10-01 | 2021-06-01 | The General Hospital Corporation | Methods for increasing efficiency of nuclease-induced homology-directed repair |
US20170327834A1 (en) | 2014-12-15 | 2017-11-16 | Syngenta Participations Ag | Pesticidal microrna carriers and use thereof |
US9963710B2 (en) | 2014-12-23 | 2018-05-08 | Syngenta Participations Ag | Methods and compositions for identifying and enriching for cells comprising site specific genomic modifications |
WO2016118726A2 (en) | 2015-01-21 | 2016-07-28 | Sangamo Biosciences, Inc. | Methods and compositions for identification of highly specific nucleases |
EP3273971A4 (en) | 2015-03-27 | 2018-12-05 | Yeda Research and Development Co. Ltd. | Methods of treating motor neuron diseases |
EP3277823B1 (en) | 2015-04-03 | 2023-09-13 | Dana-Farber Cancer Institute, Inc. | Composition and methods of genome editing of b-cells |
EP3283633A2 (en) | 2015-04-15 | 2018-02-21 | Dow AgroSciences LLC | Plant promoter for transgene expression |
KR20170136573A (ko) | 2015-04-15 | 2017-12-11 | 다우 아그로사이언시즈 엘엘씨 | 트랜스젠 발현을 위한 식물 프로모터 |
US11491342B2 (en) | 2015-07-01 | 2022-11-08 | Btl Medical Solutions A.S. | Magnetic stimulation methods and devices for therapeutic treatments |
WO2016176652A2 (en) | 2015-04-29 | 2016-11-03 | Fred Hutchinson Cancer Research Center | Modified stem cells and uses thereof |
ES2905181T3 (es) | 2015-05-01 | 2022-04-07 | Prec Biosciences Inc | Deleción precisa de secuencias cromosómicas in vivo |
ES2835861T3 (es) | 2015-05-08 | 2021-06-23 | Childrens Medical Ct Corp | Direccionamiento de regiones funcionales del potenciador de BCL11A para la reinducción de hemoglobina fetal |
WO2016182881A1 (en) | 2015-05-09 | 2016-11-17 | Two Blades Foundation | Late blight resistance gene from solanum americanum and methods of use |
EP3294280A1 (en) | 2015-05-11 | 2018-03-21 | Yeda Research and Development Co., Ltd. | Citrin inhibitors for the treatment of cancer |
CN107849142B (zh) | 2015-05-15 | 2022-04-26 | 综合医院公司 | 拮抗性抗肿瘤坏死因子受体超家族抗体 |
ES2952603T3 (es) | 2015-05-20 | 2023-11-02 | Univ California | Método para generar células dendríticas humanas para inmunoterapia |
DK3310369T3 (da) | 2015-06-19 | 2022-06-20 | Prec Biosciences Inc | Selvbegrænsende virale vektorer, der koder for nukleaser |
EP3313420B1 (en) | 2015-06-25 | 2024-03-13 | The Children's Medical Center Corporation | Methods and compositions relating to hematopoietic stem cell expansion, enrichment, and maintenance |
CA2991301A1 (en) | 2015-07-13 | 2017-01-19 | Sangamo Therapeutics, Inc. | Delivery methods and compositions for nuclease-mediated genome engineering |
EP3334750B1 (en) | 2015-08-11 | 2022-10-05 | Anie Philip | Peptidic tgf-beta antagonists |
EP3337908A4 (en) | 2015-08-18 | 2019-01-23 | The Broad Institute, Inc. | METHOD AND COMPOSITIONS FOR CHANGING THE FUNCTION AND STRUCTURE OF CHROMATIN GRINDING AND / OR DOMAINS |
CA2997909A1 (en) | 2015-09-08 | 2017-03-16 | Precision Biosciences, Inc. | Treatment of retinitis pigmentosa using engineered meganucleases |
TW201718862A (zh) | 2015-09-22 | 2017-06-01 | Dow Agrosciences Llc | 用於轉殖基因表現之植物啟動子及3’utr |
TW201718861A (zh) | 2015-09-22 | 2017-06-01 | 道禮責任有限公司 | 用於轉殖基因表現之植物啟動子及3’utr |
EP3756682B8 (en) | 2015-10-05 | 2022-04-27 | Precision Biosciences, Inc. | Genetically-modified cells comprising a modified human t cell receptor alpha constant region gene |
DK3359660T3 (en) | 2015-10-05 | 2020-02-17 | Prec Biosciences Inc | Engineered meganucleases with recognition sequences found in the human t cell receptor alpha constant region gene |
WO2017062790A1 (en) | 2015-10-09 | 2017-04-13 | Two Blades Foundation | Cold shock protein receptors and methods of use |
US10280429B2 (en) | 2015-10-22 | 2019-05-07 | Dow Agrosciences Llc | Plant promoter for transgene expression |
CN108463548B (zh) | 2015-10-30 | 2023-04-18 | 加利福尼亚大学董事会 | 由干细胞产生t细胞的方法及使用所述t细胞的免疫治疗方法 |
US20170121726A1 (en) | 2015-11-04 | 2017-05-04 | Dow Agrosciences Llc | Plant promoter for transgene expression |
WO2017079428A1 (en) | 2015-11-04 | 2017-05-11 | President And Fellows Of Harvard College | Site specific germline modification |
JP2018532415A (ja) | 2015-11-06 | 2018-11-08 | ザ ジャクソン ラボラトリー | 大きなゲノムdnaノックインおよびその使用 |
EP3377086B1 (en) | 2015-11-19 | 2024-05-01 | The Brigham and Women's Hospital, Inc. | Lymphocyte antigen cd5-like (cd5l)-interleukin 12b (p40) heterodimers in immunity |
EP3390437A4 (en) | 2015-12-18 | 2019-10-16 | Sangamo Therapeutics, Inc. | TARGETED DISORDER OF MHC CELL RECEPTOR |
JP7128741B2 (ja) | 2015-12-18 | 2022-08-31 | サンガモ セラピューティクス, インコーポレイテッド | T細胞受容体の標的化破壊 |
CA3009637A1 (en) | 2015-12-23 | 2017-06-29 | Precision Biosciences, Inc. | Engineered meganucleases with recognition sequences found in the human beta-2 microglobulin gene |
US10828318B2 (en) | 2016-01-06 | 2020-11-10 | Yeda Research And Development Co. Ltd. | Compositions and methods for treating malignant, autoimmune and inflammatory diseases |
KR20180095719A (ko) | 2016-01-11 | 2018-08-27 | 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 | 키메라 단백질 및 면역요법 방법 |
US9856497B2 (en) | 2016-01-11 | 2018-01-02 | The Board Of Trustee Of The Leland Stanford Junior University | Chimeric proteins and methods of regulating gene expression |
JP7019580B2 (ja) | 2016-01-21 | 2022-02-15 | ザ ステイト オブ イスラエル ミニストリー オブ アグリカルチャー アンド ルーラル ディベロップメント アグリカルチュラル リサーチ オーガニゼイション (エー.アール.オー.) (ボルカニ センター) | 単為結実植物およびその製造方法 |
WO2017130205A1 (en) | 2016-01-31 | 2017-08-03 | Hadasit Medical Research Services And Development Ltd. | Autosomal-identical pluripotent stem cell populations having non-identical sex chromosomal composition and uses thereof |
EP3769775A3 (en) | 2016-02-02 | 2021-03-17 | Sangamo Therapeutics, Inc. | Compositions for linking dna-binding domains and cleavage domains |
US20190046497A1 (en) | 2016-02-14 | 2019-02-14 | Yeda Research And Development Co., Ltd. | Methods of modulating protein exocytosis and uses of same in therapy |
CN109069870B (zh) | 2016-02-24 | 2022-04-29 | 洛克菲勒大学 | 基于胚胎细胞的用于亨廷顿氏病的治疗候选物筛选系统、模型及它们的应用 |
WO2017153982A1 (en) | 2016-03-06 | 2017-09-14 | Yeda Research And Development Co. Ltd. | Method for modulating myelination |
WO2017161001A1 (en) | 2016-03-15 | 2017-09-21 | Children's Medical Center Corporation | Methods and compositions relating to hematopoietic stem cell expansion |
NZ745936A (en) | 2016-04-27 | 2020-02-28 | Univ Puerto Rico | 1,5-disubstituted 1,2,3-triazoles are inhibitors of rac/cdc42 gtpases |
ES2905791T3 (es) | 2016-05-03 | 2022-04-12 | Prec Biosciences Inc | Nucleasas de ingeniería útiles para el tratamiento de la hemofilia A |
CN109415737A (zh) | 2016-05-25 | 2019-03-01 | 嘉吉公司 | 用于在植物中产生突变的工程化核酸酶 |
MX2018014496A (es) | 2016-05-26 | 2019-03-28 | Nunhems Bv | Plantas productoras de frutas sin semillas. |
US11859232B2 (en) | 2016-06-19 | 2024-01-02 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Screening for chemotherapy resistance in human haploid cells |
BR112018076811A2 (pt) | 2016-06-22 | 2019-08-27 | Univ North Carolina State | métodos, usos, construção ou vetor, célula, planta, material de propagação de planta, folha colhida, folha processada, produto de planta, produto de tabaco, extrato de planta e artigo de fumar |
US20190247436A1 (en) | 2016-07-21 | 2019-08-15 | Maxcyte, Inc. | Methods and compositions for modifying genomic dna |
IL247368A0 (en) | 2016-08-18 | 2016-11-30 | Yeda Res & Dev | Diagnostic and therapeutic uses of exosomes |
KR20220145913A (ko) | 2016-08-24 | 2022-10-31 | 상가모 테라퓨틱스, 인코포레이티드 | 가공된 표적 특이적 뉴클레아제 |
US20190225974A1 (en) | 2016-09-23 | 2019-07-25 | BASF Agricultural Solutions Seed US LLC | Targeted genome optimization in plants |
CN109996868A (zh) | 2016-09-23 | 2019-07-09 | 弗雷德哈钦森癌症研究中心 | 特异性用于次要组织相容性(h)抗原ha-1的tcr及其用途 |
US10519459B2 (en) | 2016-10-03 | 2019-12-31 | Dow Agrosciences Llc | Plant promoter from Panicum virgatum |
EP3519574B1 (en) | 2016-10-03 | 2022-01-19 | Corteva Agriscience LLC | Plant promoter for transgene expression |
EP3757120B8 (en) | 2016-10-04 | 2022-06-15 | Precision Biosciences, Inc. | Co-stimulatory domains for use in genetically-modified cells |
KR102305215B1 (ko) * | 2016-10-14 | 2021-09-28 | 프리시젼 바이오사이언시스 인코포레이티드 | B형 간염 바이러스 게놈 내의 인식 서열에 대해 특이적인 조작된 메가뉴클레아제 |
WO2018073393A2 (en) | 2016-10-19 | 2018-04-26 | Cellectis | Tal-effector nuclease (talen) -modified allogenic cells suitable for therapy |
CN110022904B (zh) | 2016-10-20 | 2024-04-19 | 桑格摩生物治疗股份有限公司 | 用于治疗法布里病的方法和组合物 |
WO2018081775A1 (en) | 2016-10-31 | 2018-05-03 | Sangamo Therapeutics, Inc. | Gene correction of scid-related genes in hematopoietic stem and progenitor cells |
WO2018076335A1 (en) | 2016-10-31 | 2018-05-03 | Institute Of Genetics And Developmental Biology, Chinese Academy Of Sciences | Compositions and methods for enhancing abiotic stress tolerance |
CN110249051A (zh) | 2016-12-08 | 2019-09-17 | 凯斯西储大学 | 增强功能性髓鞘产生的方法和组合物 |
US20200124615A1 (en) | 2016-12-29 | 2020-04-23 | Ukko Inc. | Methods for identifying and de-epitoping allergenic polypeptides |
AU2018234830B2 (en) | 2017-03-15 | 2023-03-02 | Fred Hutchinson Cancer Center | High affinity MAGE-A1-specific TCRs and uses thereof |
WO2018183908A1 (en) | 2017-03-31 | 2018-10-04 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for treating ovarian tumors |
US20210115407A1 (en) | 2017-04-12 | 2021-04-22 | The Broad Institute, Inc. | Respiratory and sweat gland ionocytes |
BR112019021282A2 (pt) | 2017-04-12 | 2020-05-19 | Magenta Therapeutics Inc | antagonistas de receptor aril hidrocarboneto e usos dos mesmos |
EP3610266A4 (en) | 2017-04-12 | 2021-04-21 | Massachusetts Eye and Ear Infirmary | TUMOR SIGNATURE OF METASTASIS, COMPOSITIONS OF SUBSTANCES AND USES THEREOF |
WO2018195486A1 (en) | 2017-04-21 | 2018-10-25 | The Broad Institute, Inc. | Targeted delivery to beta cells |
CN110769845B (zh) | 2017-04-21 | 2023-08-15 | 精密生物科学公司 | 对pcsk9基因中的识别序列具有特异性的工程化大范围核酸酶 |
US11820728B2 (en) | 2017-04-28 | 2023-11-21 | Acuitas Therapeutics, Inc. | Carbonyl lipids and lipid nanoparticle formulations for delivery of nucleic acids |
WO2018201144A1 (en) | 2017-04-28 | 2018-11-01 | Precision Biosciences, Inc. | Methods for reducing dna-induced cytotoxicity and enhancing gene editing in primary cells |
EP3619322A4 (en) | 2017-05-03 | 2021-06-30 | Sangamo Therapeutics, Inc. | METHODS AND COMPOSITIONS FOR MODIFICATION OF A TRANSMEMBRANARY CONDUCTANCE REGULATORY GENE IN MUCOVISCIDOSIS (CFTR) |
US11591601B2 (en) | 2017-05-05 | 2023-02-28 | The Broad Institute, Inc. | Methods for identification and modification of lncRNA associated with target genotypes and phenotypes |
IL252151A0 (en) | 2017-05-07 | 2017-07-31 | Fainzilber Michael | Treatment of stress disorders |
CA3062698A1 (en) | 2017-05-08 | 2018-11-15 | Precision Biosciences, Inc. | Nucleic acid molecules encoding an engineered antigen receptor and an inhibitory nucleic acid molecule and methods of use thereof |
CA3064000A1 (en) | 2017-05-24 | 2018-11-29 | Effector Therapeutics, Inc. | Methods and compositions for cellular immunotherapy |
GB201708662D0 (en) | 2017-05-31 | 2017-07-12 | Tropic Biosciences Uk Ltd | Compositions and methods for increasing shelf-life of banana |
GB201708665D0 (en) | 2017-05-31 | 2017-07-12 | Tropic Biosciences Uk Ltd | Compositions and methods for increasing extractability of solids from coffee beans |
WO2018220582A1 (en) | 2017-05-31 | 2018-12-06 | Tropic Biosciences UK Limited | Methods of selecting cells comprising genome editing events |
WO2018224861A1 (en) | 2017-06-07 | 2018-12-13 | International Rice Research Institute | Increasing hybrid seed production through higher outcrossing rate in cytoplasmic male sterile gramineae plants and related materials and methods |
WO2018232195A1 (en) | 2017-06-14 | 2018-12-20 | The Broad Institute, Inc. | Compositions and methods targeting complement component 3 for inhibiting tumor growth |
US20200291413A1 (en) | 2017-06-23 | 2020-09-17 | University Of Kentucky Research Foundation | Method |
WO2019005884A1 (en) | 2017-06-26 | 2019-01-03 | The Broad Institute, Inc. | CRISPR / CAS-ADENINE DEAMINASE COMPOSITIONS, SYSTEMS AND METHODS FOR TARGETED NUCLEIC ACID EDITION |
WO2019005957A1 (en) | 2017-06-30 | 2019-01-03 | Precision Biosciences, Inc. | GENETICALLY MODIFIED T CELLS COMPRISING A MODIFIED INTRON IN THE ALPHA T CELL RECEPTOR GENE |
IL253642A0 (en) | 2017-07-24 | 2017-09-28 | Seger Rony | Combined treatment for cancer |
CA3071440C (en) | 2017-07-31 | 2023-09-26 | R. J. Reynolds Tobacco Company | Methods and compositions for viral-based gene editing in plants |
US10430138B2 (en) * | 2017-08-10 | 2019-10-01 | Canon Kabushiki Kaisha | Communication apparatus |
US11692166B2 (en) | 2017-08-23 | 2023-07-04 | Technion Research & Development Foundation Limited | Compositions and methods for improving alcohol tolerance in yeast |
WO2019051135A1 (en) | 2017-09-06 | 2019-03-14 | Fred Hutchinson Cancer Research Center | METHODS FOR IMPROVING ADOPTIVE CELL THERAPY |
AU2018327225A1 (en) | 2017-09-06 | 2020-02-27 | Fred Hutchinson Cancer Center | Strep-tag specific chimeric receptors and uses thereof |
KR20230050424A (ko) | 2017-09-19 | 2023-04-14 | 트로픽 바이오사이언시즈 유케이 리미티드 | 유전자 발현을 침묵시키기 위한 식물의 비-암호화 rna 분자의 특이성 변형 |
WO2019070856A1 (en) | 2017-10-03 | 2019-04-11 | Precision Biosciences, Inc. | MODIFIED EPIDERMAL GROWTH FACTOR RECEPTOR PEPTIDES FOR USE IN GENETICALLY MODIFIED CELLS |
US20200255828A1 (en) | 2017-10-04 | 2020-08-13 | The Broad Institute, Inc. | Methods and compositions for altering function and structure of chromatin loops and/or domains |
WO2019079777A1 (en) | 2017-10-20 | 2019-04-25 | Fred Hutchinson Cancer Research Center | COMPOSITIONS AND METHODS FOR TIGIT AND / OR CD112R TARGETING IMMUNOTHERAPY OR COMPRISING THE OVEREXPRESSION OF CD226 |
WO2019089833A1 (en) | 2017-10-31 | 2019-05-09 | Magenta Therapeutics Inc. | Compositions and methods for hematopoietic stem and progenitor cell transplant therapy |
AU2018358241A1 (en) | 2017-10-31 | 2020-05-07 | Edigene Biotechnology, Inc. | Compositions and methods for the expansion of hematopoietic stem and progenitor cells |
US20200299658A1 (en) | 2017-11-01 | 2020-09-24 | Precision Biosciences, Inc. | Engineered nucleases that target human and canine factor viii genes as a treatment for hemophilia a |
WO2019094725A2 (en) | 2017-11-09 | 2019-05-16 | Sangamo Therapeutics, Inc. | Genetic modification of cytokine inducible sh2-containing protein (cish) gene |
EP3710039A4 (en) | 2017-11-13 | 2021-08-04 | The Broad Institute, Inc. | METHODS AND COMPOSITIONS FOR CANCER TREATMENT BY TARGETING THE CLEC2D-KLRB1 PATH |
IL255664A0 (en) | 2017-11-14 | 2017-12-31 | Shachar Idit | Hematopoietic stem cells with enhanced properties |
WO2019108619A1 (en) | 2017-11-28 | 2019-06-06 | Two Blades Foundation | Methods and compositions for enhancing the disease resistance of plants |
WO2019109047A1 (en) | 2017-12-01 | 2019-06-06 | Fred Hutchinson Cancer Research Center | Binding proteins specific for 5t4 and uses thereof |
EP3707642A1 (en) | 2017-12-03 | 2020-09-16 | Seedx Technologies Inc. | Systems and methods for sorting of seeds |
EP3707641A2 (en) | 2017-12-03 | 2020-09-16 | Seedx Technologies Inc. | Systems and methods for sorting of seeds |
US11504748B2 (en) | 2017-12-03 | 2022-11-22 | Seedx Technologies Inc. | Systems and methods for sorting of seeds |
JP2021505172A (ja) | 2017-12-06 | 2021-02-18 | マジェンタ セラピューティクス インコーポレイテッドMagenta Therapeutics, Inc. | 造血幹細胞及び前駆細胞を動員させるための投薬レジメン |
CN111902411A (zh) | 2018-01-03 | 2020-11-06 | 美真达治疗公司 | 用于扩增造血干细胞和祖细胞以及治疗遗传性代谢紊乱的组合物和方法 |
US11994512B2 (en) | 2018-01-04 | 2024-05-28 | Massachusetts Institute Of Technology | Single-cell genomic methods to generate ex vivo cell systems that recapitulate in vivo biology with improved fidelity |
WO2019140278A1 (en) | 2018-01-11 | 2019-07-18 | Fred Hutchinson Cancer Research Center | Immunotherapy targeting core binding factor antigens |
AU2019207409B2 (en) | 2018-01-12 | 2023-02-23 | Basf Se | Gene underlying the number of spikelets per spike qtl in wheat on chromosome 7a |
US11732271B2 (en) | 2018-01-12 | 2023-08-22 | The Sainsbury Laboratory | Stem rust resistance genes and methods of use |
EP3749368A1 (en) | 2018-02-08 | 2020-12-16 | Yeda Research and Development Co. Ltd | Methods of identifying and using agents for treating diseases associated with intestinal barrier dysfunction |
AU2019224051A1 (en) | 2018-02-26 | 2020-09-03 | Fred Hutchinson Cancer Center | Compositions and methods for cellular immunotherapy |
CN111936617A (zh) | 2018-03-16 | 2020-11-13 | 益缪索夫特公司 | 经遗传工程化以分泌卵泡抑素的b细胞以及使用所述b细胞来治疗卵泡抑素相关的疾病、病况、病症及增强肌肉生长和力量的方法 |
IT201800004253A1 (it) | 2018-04-05 | 2019-10-05 | Composizioni e metodi per il trattamento della tachicardia ventricolare polimorfa catecolaminergica dominante ereditaria. | |
AU2019252527B2 (en) | 2018-04-12 | 2024-02-22 | Precision Biosciences, Inc. | Optimized engineered nucleases having specificity for the human T cell receptor alpha constant region gene |
US11142750B2 (en) | 2018-04-12 | 2021-10-12 | Precision Biosciences, Inc. | Optimized engineered meganucleases having specificity for a recognition sequence in the Hepatitis B virus genome |
EP3781685A1 (en) | 2018-04-18 | 2021-02-24 | B.R.A.I.N. Biotechnology Research and Information Network AG | Enrichment of genome-edited cells |
HUE059223T2 (hu) | 2018-04-24 | 2022-10-28 | Kws Saat Se & Co Kgaa | Jobb emészthetõségû növények és marker haplotípusok |
US11957695B2 (en) | 2018-04-26 | 2024-04-16 | The Broad Institute, Inc. | Methods and compositions targeting glucocorticoid signaling for modulating immune responses |
WO2019210268A2 (en) | 2018-04-27 | 2019-10-31 | The Broad Institute, Inc. | Sequencing-based proteomics |
GB201807192D0 (en) | 2018-05-01 | 2018-06-13 | Tropic Biosciences Uk Ltd | Compositions and methods for reducing caffeine content in coffee beans |
WO2019213660A2 (en) | 2018-05-04 | 2019-11-07 | The Broad Institute, Inc. | Compositions and methods for modulating cgrp signaling to regulate innate lymphoid cell inflammatory responses |
US11690921B2 (en) | 2018-05-18 | 2023-07-04 | Sangamo Therapeutics, Inc. | Delivery of target specific nucleases |
US20210371932A1 (en) | 2018-06-01 | 2021-12-02 | Massachusetts Institute Of Technology | Methods and compositions for detecting and modulating microenvironment gene signatures from the csf of metastasis patients |
EP3806619A1 (en) | 2018-06-15 | 2021-04-21 | Nunhems B.V. | Seedless watermelon plants comprising modifications in an abc transporter gene |
US11873322B2 (en) | 2018-06-25 | 2024-01-16 | Yeda Research And Development Co. Ltd. | Systems and methods for increasing efficiency of genome editing |
US20210292381A1 (en) | 2018-07-04 | 2021-09-23 | Ukko Inc. | Methods of de-epitoping wheat proteins and use of same for the treatment of celiac disease |
WO2020018964A1 (en) | 2018-07-20 | 2020-01-23 | Fred Hutchinson Cancer Research Center | Compositions and methods for controlled expression of antigen-specific receptors |
GB201812603D0 (en) | 2018-08-02 | 2018-09-19 | British American Tobacco Investments Ltd | Method |
US20210317429A1 (en) | 2018-08-20 | 2021-10-14 | The Broad Institute, Inc. | Methods and compositions for optochemical control of crispr-cas9 |
CA3109496A1 (en) | 2018-08-22 | 2020-02-27 | Fred Hutchinson Cancer Research Center | Immunotherapy targeting kras or her2 antigens |
WO2020047099A1 (en) | 2018-08-28 | 2020-03-05 | Fred Hutchinson Cancer Research Center | Methods and compositions for adoptive t cell therapy incorporating induced notch signaling |
CA3111392A1 (en) | 2018-09-04 | 2020-03-12 | Magenta Therapeutics, Inc. | Aryl hydrocarbon receptor antagonists and methods of use |
US20220088224A1 (en) | 2018-09-18 | 2022-03-24 | Vnv Newco Inc. | Arc-based capsids and uses thereof |
JP2022500052A (ja) | 2018-09-18 | 2022-01-04 | サンガモ セラピューティクス, インコーポレイテッド | プログラム細胞死1(pd1)特異的ヌクレアーゼ |
US20240165232A1 (en) | 2018-09-24 | 2024-05-23 | Fred Hutchinson Cancer Research Center | Chimeric receptor proteins and uses thereof |
WO2020077236A1 (en) | 2018-10-12 | 2020-04-16 | The Broad Institute, Inc. | Method for extracting nuclei or whole cells from formalin-fixed paraffin-embedded tissues |
US20210379057A1 (en) | 2018-10-16 | 2021-12-09 | Massachusetts Institute Of Technology | Nutlin-3a for use in treating a mycobacterium tuberculosis infection |
IL262658A (en) | 2018-10-28 | 2020-04-30 | Memorial Sloan Kettering Cancer Center | Prevention of age related clonal hematopoiesis and diseases associated therewith |
GB201817971D0 (en) | 2018-11-02 | 2018-12-19 | British American Tobacco Investments Ltd | Method |
CA3119188A1 (en) | 2018-11-09 | 2020-05-14 | Fred Hutchinson Cancer Research Center | T cell receptors specific for mesothelin and their use in immunotherapy |
GB201818715D0 (en) | 2018-11-16 | 2019-01-02 | British American Tobacco Investments Ltd | Method |
WO2020131862A1 (en) | 2018-12-17 | 2020-06-25 | The Broad Institute, Inc. | Crispr-associated transposase systems and methods of use thereof |
EP3898661A1 (en) | 2018-12-21 | 2021-10-27 | Precision BioSciences, Inc. | Genetic modification of the hydroxyacid oxidase 1 gene for treatment of primary hyperoxaluria |
CA3123890A1 (en) | 2019-01-04 | 2020-07-09 | Cargill Incorporated | Engineered nucleases to generate mutations in plants |
US11739156B2 (en) | 2019-01-06 | 2023-08-29 | The Broad Institute, Inc. Massachusetts Institute of Technology | Methods and compositions for overcoming immunosuppression |
AU2020205717A1 (en) | 2019-01-11 | 2021-08-12 | Acuitas Therapeutics, Inc. | Lipids for lipid nanoparticle delivery of active agents |
GB201900940D0 (en) | 2019-01-23 | 2019-03-13 | British American Tobacco Investments Ltd | Method |
CN112805026A (zh) | 2019-02-06 | 2021-05-14 | 桑格摩生物治疗股份有限公司 | 用于治疗i型黏多糖贮积症的方法 |
US20230053540A1 (en) | 2019-02-19 | 2023-02-23 | Massachusetts Institute Of Technology | Treatment of liver injury |
CN114026116A (zh) | 2019-02-20 | 2022-02-08 | 弗雷德哈钦森癌症研究中心 | Ras新抗原特异性结合蛋白及其用途 |
EP3927378A1 (en) | 2019-02-21 | 2021-12-29 | Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. | Method for reduction drug-induced nephrotoxicity |
CA3128360A1 (en) | 2019-03-05 | 2020-09-10 | Yuval CINNAMON | Genome-edited birds |
CA3132845A1 (en) | 2019-03-11 | 2020-09-17 | Fred Hutchinson Cancer Research Center | High avidity wt1 t cell receptors and uses thereof |
US20220154282A1 (en) | 2019-03-12 | 2022-05-19 | The Broad Institute, Inc. | Detection means, compositions and methods for modulating synovial sarcoma cells |
WO2020186237A1 (en) | 2019-03-13 | 2020-09-17 | The Broad Institute, Inc. | Microglial progenitors for regeneration of functional microglia in the central nervous system and therapeutics uses thereof |
EP3937969A1 (en) | 2019-03-14 | 2022-01-19 | The Broad Institute, Inc. | Compositions and methods for modulating cgrp signaling to regulate intestinal innate lymphoid cells |
GB201903521D0 (en) | 2019-03-14 | 2019-05-01 | Tropic Biosciences Uk Ltd | No title |
GB201903520D0 (en) | 2019-03-14 | 2019-05-01 | Tropic Biosciences Uk Ltd | Modifying the specificity of non-coding rna molecules for silencing genes in eukaryotic cells |
GB201903519D0 (en) | 2019-03-14 | 2019-05-01 | Tropic Biosciences Uk Ltd | Introducing silencing activity to dysfunctional rna molecules and modifying their specificity against a gene of interest |
WO2020191069A1 (en) | 2019-03-18 | 2020-09-24 | The Broad Institute, Inc. | Modulation of type 2 immunity by targeting clec-2 signaling |
EP3942023A1 (en) | 2019-03-18 | 2022-01-26 | The Broad Institute, Inc. | Compositions and methods for modulating metabolic regulators of t cell pathogenicity |
WO2020205838A1 (en) | 2019-04-02 | 2020-10-08 | Sangamo Therapeutics, Inc. | Methods for the treatment of beta-thalassemia |
CA3135799A1 (en) | 2019-04-03 | 2020-10-08 | Precision Biosciences, Inc. | Genetically-modified immune cells comprising a microrna-adapted shrna (shrnamir) |
CA3136265A1 (en) | 2019-04-05 | 2020-10-08 | Precision Biosciences, Inc. | Methods of preparing populations of genetically-modified immune cells |
KR20220005555A (ko) | 2019-05-07 | 2022-01-13 | 프리시젼 바이오사이언시스 인코포레이티드 | 인식 서열에 대한 조작된 메가뉴클레아제의 최적화 |
EP3969607A1 (en) | 2019-05-13 | 2022-03-23 | KWS SAAT SE & Co. KGaA | Drought tolerance in corn |
GB201906768D0 (en) | 2019-05-14 | 2019-06-26 | British American Tobacco Investments Ltd | Method |
US20220249701A1 (en) | 2019-05-14 | 2022-08-11 | The Broad Institute, Inc. | Compositions and methods for targeting multinucleated cells |
AR118995A1 (es) | 2019-05-25 | 2021-11-17 | Kws Saat Se & Co Kgaa | Mejorador de la inducción de haploides |
WO2020243371A1 (en) | 2019-05-28 | 2020-12-03 | Massachusetts Institute Of Technology | Methods and compositions for modulating immune responses |
WO2020243661A1 (en) | 2019-05-31 | 2020-12-03 | The Broad Institute, Inc. | Methods for treating metabolic disorders by targeting adcy5 |
BR112021026248A2 (pt) | 2019-06-27 | 2022-03-03 | Two Blades Found | Molécula de ácido nucleico isolada que codifica uma proteína atrlp23 engenheirada, proteína atrlp23 engenheirada, cassete de expressão, vetor, célula hospedeira, planta ou célula vegetal, métodos para fazer uma proteína atrlp23 engenheirada, para fazer uma molécula de ácido nucleico que codifica uma proteína atrlp23 engenheirada e para intensificar a resistência de uma planta |
GB201909562D0 (en) | 2019-07-03 | 2019-08-14 | British American Tobacco Investments Ltd | Method |
GB201909563D0 (en) | 2019-07-03 | 2019-08-14 | British American Tobacco Investments Ltd | Method |
US20220251148A1 (en) | 2019-07-04 | 2022-08-11 | Ukko Inc. | De-epitoped alpha gliadin and use of same for the management of celiac disease and gluten sensitivity |
WO2021011348A1 (en) | 2019-07-12 | 2021-01-21 | The Regents Of The University Of California | Plants with enhanced resistance to bacterial pathogens |
WO2021009692A1 (en) | 2019-07-15 | 2021-01-21 | Medimmune Limited | Tripartite systems for protein dimerization and methods of use |
IL268111A (en) | 2019-07-16 | 2021-01-31 | Fainzilber Michael | Methods of treating pain |
US20220273715A1 (en) | 2019-07-25 | 2022-09-01 | Precision Biosciences, Inc. | Compositions and methods for sequential stacking of nucleic acid sequences into a genomic locus |
WO2021019536A1 (en) | 2019-07-30 | 2021-02-04 | The State Of Israel, Ministry Of Agriculture & Rural Development, Agricultural Research Organization (Aro) (Volcani Center) | Methods of controlling cannabinoid synthesis in plants or cells and plants and cells produced thereby |
US20220267732A1 (en) | 2019-08-01 | 2022-08-25 | Sana Biotechnology, Inc. | Dux4 expressing cells and uses thereof |
EP3772542A1 (en) | 2019-08-07 | 2021-02-10 | KWS SAAT SE & Co. KGaA | Modifying genetic variation in crops by modulating the pachytene checkpoint protein 2 |
US20220282333A1 (en) | 2019-08-13 | 2022-09-08 | The General Hospital Corporation | Methods for predicting outcomes of checkpoint inhibition and treatment thereof |
CN114555790A (zh) | 2019-08-20 | 2022-05-27 | 弗雷德哈钦森癌症研究中心 | Wt-1特异性t细胞免疫疗法 |
AU2020333851A1 (en) | 2019-08-20 | 2022-03-31 | Precision Biosciences, Inc. | Lymphodepletion dosing regimens for cellular immunotherapies |
WO2021035170A1 (en) | 2019-08-21 | 2021-02-25 | Precision Biosciences, Inc. | Compositions and methods for tcr reprogramming using fusion proteins |
EP4017508A1 (en) | 2019-08-23 | 2022-06-29 | Sana Biotechnology, Inc. | Cd24 expressing cells and uses thereof |
WO2021041922A1 (en) | 2019-08-30 | 2021-03-04 | The Broad Institute, Inc. | Crispr-associated mu transposase systems |
JP2022550608A (ja) | 2019-10-02 | 2022-12-02 | サンガモ セラピューティクス, インコーポレイテッド | プリオン病の治療のためのジンクフィンガータンパク質転写因子 |
US20220324928A1 (en) | 2019-10-02 | 2022-10-13 | Sangamo Therapeutics, Inc. | Zinc Finger Protein Transcription Factors for Repressing Alpha-Synuclein Expression |
US11981922B2 (en) | 2019-10-03 | 2024-05-14 | Dana-Farber Cancer Institute, Inc. | Methods and compositions for the modulation of cell interactions and signaling in the tumor microenvironment |
US11793787B2 (en) | 2019-10-07 | 2023-10-24 | The Broad Institute, Inc. | Methods and compositions for enhancing anti-tumor immunity by targeting steroidogenesis |
CN114846022A (zh) | 2019-10-17 | 2022-08-02 | 科沃施种子欧洲股份两合公司 | 通过阻抑基因的下调增强作物的疾病抗性 |
IL270306A (en) | 2019-10-30 | 2021-05-31 | Yeda Res & Dev | Prevention and treatment of pre-myeloid and myeloid malignancies |
WO2021087305A1 (en) | 2019-10-30 | 2021-05-06 | Precision Biosciences, Inc. | Cd20 chimeric antigen receptors and methods of use for immunotherapy |
US11844800B2 (en) | 2019-10-30 | 2023-12-19 | Massachusetts Institute Of Technology | Methods and compositions for predicting and preventing relapse of acute lymphoblastic leukemia |
EP4051298A1 (en) | 2019-11-01 | 2022-09-07 | Magenta Therapeutics, Inc. | Dosing regimens for the mobilization of hematopoietic stem and progentor cells |
US20230022576A1 (en) | 2019-11-19 | 2023-01-26 | Protalix Ltd. | Removal of constructs from transformed cells |
WO2021113543A1 (en) | 2019-12-06 | 2021-06-10 | Precision Biosciences, Inc. | Methods for cancer immunotherapy, using lymphodepletion regimens and cd19, cd20 or bcma allogeneic car t cells |
WO2021113765A1 (en) | 2019-12-06 | 2021-06-10 | Precision Biosciences, Inc. | Optimized engineered meganucleases having specificity for a recognition sequence in the hepatitis b virus genome |
EP3835309A1 (en) | 2019-12-13 | 2021-06-16 | KWS SAAT SE & Co. KGaA | Method for increasing cold or frost tolerance in a plant |
IL271656A (en) | 2019-12-22 | 2021-06-30 | Yeda Res & Dev | System and methods for identifying cells that have undergone genome editing |
EP4096647A1 (en) | 2020-01-30 | 2022-12-07 | Yeda Research and Development Co. Ltd | Treating acute liver disease with tlr-mik inhibitors |
WO2021158915A1 (en) | 2020-02-06 | 2021-08-12 | Precision Biosciences, Inc. | Recombinant adeno-associated virus compositions and methods for producing and using the same |
JP2023520997A (ja) | 2020-03-25 | 2023-05-23 | サナ バイオテクノロジー,インコーポレイテッド | 神経学的障害及び神経学的病態の処置のための低免疫原性神経細胞 |
CN115697044A (zh) | 2020-03-31 | 2023-02-03 | 艾洛生物系统有限公司 | 西瓜和其他葫芦科中内源罗汉果苷途径基因的调控 |
KR20220165764A (ko) | 2020-04-09 | 2022-12-15 | 아아르. 제이. 레날드즈 토바코 캄파니 | 니코티아나 타바쿰에서 니코틴 수준을 조절하는 방법 |
CA3176979A1 (en) | 2020-04-27 | 2021-11-04 | Anthony Boitano | Methods and compositions for transducing hematopoietic stem and progenitor cells in vivo |
JP2023525513A (ja) | 2020-05-06 | 2023-06-16 | セレクティス ソシエテ アノニム | 細胞ゲノムにおける外因性配列の標的化挿入のための方法 |
EP4146284A1 (en) | 2020-05-06 | 2023-03-15 | Cellectis S.A. | Methods to genetically modify cells for delivery of therapeutic proteins |
WO2021231259A1 (en) | 2020-05-11 | 2021-11-18 | Precision Biosciences, Inc. | Self-limiting viral vectors encoding nucleases |
JP2023526310A (ja) | 2020-05-12 | 2023-06-21 | ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア | 導入遺伝子発現のdrg特異的低減のための組成物 |
EP4150068A1 (en) | 2020-05-12 | 2023-03-22 | Precision BioSciences, Inc. | Treatment of retinitis pigmentosa using improved engineered meganucleases |
US20230190871A1 (en) | 2020-05-20 | 2023-06-22 | Sana Biotechnology, Inc. | Methods and compositions for treatment of viral infections |
UY39237A (es) | 2020-05-29 | 2021-12-31 | Kws Saat Se & Co Kgaa | Inducción de haploides en plantas |
CN116096702A (zh) | 2020-07-16 | 2023-05-09 | 爱康泰生治疗公司 | 用于脂质纳米颗粒的阳离子脂质 |
EP4192875A1 (en) | 2020-08-10 | 2023-06-14 | Precision BioSciences, Inc. | Antibodies and fragments specific for b-cell maturation antigen and uses thereof |
WO2022036150A1 (en) | 2020-08-13 | 2022-02-17 | Sana Biotechnology, Inc. | Methods of treating sensitized patients with hypoimmunogenic cells, and associated methods and compositions |
US20230309480A1 (en) | 2020-08-18 | 2023-10-05 | International Rice Research Institute | Methods of increasing outcrossing rates in gramineae |
AU2021329403A1 (en) | 2020-08-21 | 2023-05-04 | Precision Biosciences, Inc. | Engineered meganucleases having specificity for a recognition sequence in the transthyretin gene |
WO2022046760A2 (en) | 2020-08-25 | 2022-03-03 | Kite Pharma, Inc. | T cells with improved functionality |
WO2022066965A2 (en) | 2020-09-24 | 2022-03-31 | Fred Hutchinson Cancer Research Center | Immunotherapy targeting sox2 antigens |
WO2022066973A1 (en) | 2020-09-24 | 2022-03-31 | Fred Hutchinson Cancer Research Center | Immunotherapy targeting pbk or oip5 antigens |
KR20230074519A (ko) | 2020-09-25 | 2023-05-30 | 상가모 테라퓨틱스, 인코포레이티드 | 핵염기 편집을 위한 아연 핑거 융합 단백질 |
WO2022074646A1 (en) | 2020-10-05 | 2022-04-14 | Protalix Ltd. | Dicer-like knock-out plant cells |
TW202222841A (zh) | 2020-10-06 | 2022-06-16 | 福瑞德哈金森腫瘤研究中心 | 用於治療表現mage-a1之疾病的組成物及方法 |
US20230365995A1 (en) | 2020-10-07 | 2023-11-16 | Precision Biosciences, Inc. | Lipid nanoparticle compositions |
WO2022079719A1 (en) | 2020-10-15 | 2022-04-21 | Yeda Research And Development Co. Ltd. | Method of treating myeloid malignancies |
WO2022087527A1 (en) | 2020-10-23 | 2022-04-28 | Elo Life Systems, Inc. | Methods for producing vanilla plants with improved flavor and agronomic production |
EP4236975A1 (en) | 2020-10-29 | 2023-09-06 | The Trustees of The University of Pennsylvania | Aav capsids and compositions containing same |
KR20230118841A (ko) | 2020-11-12 | 2023-08-14 | 프리시젼 바이오사이언시스 인코포레이티드 | 디스트로핀 유전자 내의 인식 서열에 대해 특이성을 갖는 조작된 메가뉴클레아제 |
WO2022115498A1 (en) | 2020-11-26 | 2022-06-02 | Ukko Inc. | Modified high molecular weight glutenin subunit and uses thereof |
CA3201767A1 (en) | 2020-12-14 | 2022-06-23 | Thomas M. Schmitt | Compositions and methods for cellular immunotherapy |
IL279559A (en) | 2020-12-17 | 2022-07-01 | Yeda Res & Dev | Controlling the ubiquitination process of mlkl for disease treatment |
IL303473A (en) | 2020-12-31 | 2023-08-01 | Sana Biotechnology Inc | Methods and compositions for modulating CAR-T activity |
WO2022150616A1 (en) | 2021-01-08 | 2022-07-14 | Precision Biosciences, Inc. | Engineered meganucleases having specificity for a recognition sequence in the hydroxyacid oxidase 1 gene |
EP4284823A1 (en) | 2021-01-28 | 2023-12-06 | Precision BioSciences, Inc. | Modulation of tgf beta signaling in genetically-modified eukaryotic cells |
EP4308694A1 (en) | 2021-03-16 | 2024-01-24 | Magenta Therapeutics, Inc. | Dosing regimens for hematopoietic stem cell mobilization for stem cell transplants in multiple myeloma patients |
US20240141311A1 (en) | 2021-04-22 | 2024-05-02 | North Carolina State University | Compositions and methods for generating male sterile plants |
EP4326861A1 (en) | 2021-04-22 | 2024-02-28 | Precision Biosciences, Inc. | Engineered meganucleases that target human mitochondrial genomes |
EP4326862A1 (en) | 2021-04-22 | 2024-02-28 | Precision Biosciences, Inc. | Engineered meganucleases that target human mitochondrial genomes |
AR125467A1 (es) | 2021-04-27 | 2023-07-19 | Univ Pennsylvania | Cápsides de virus adenoasociados derivados de porcinos y usos de los estos |
KR20240017813A (ko) | 2021-05-10 | 2024-02-08 | 이슘 리서치 디벨롭먼트 컴퍼니 오브 더 히브루 유니버시티 오브 예루살렘 엘티디. | 신경질환 치료용 약학적 조성물 |
WO2022240931A1 (en) | 2021-05-11 | 2022-11-17 | Two Blades Foundation | Methods for preparing a library of plant disease resistance genes for functional testing for disease resistance |
WO2022242644A1 (zh) | 2021-05-18 | 2022-11-24 | 赛斯尔擎生物技术(上海)有限公司 | 修饰细胞的方法 |
BR112023024434A2 (pt) | 2021-05-27 | 2024-02-20 | Sana Biotechnology Inc | Células hipoimunogênicas que compreendem hla-e ou hla-g geneticamente modificadas |
JP2024524924A (ja) | 2021-07-02 | 2024-07-09 | トロピック バイオサイエンシーズ ユーケー リミテッド | バナナ果実における褐変の遅延又は防止 |
AU2022309875A1 (en) | 2021-07-14 | 2024-01-25 | Sana Biotechnology, Inc. | Altered expression of y chromosome-linked antigens in hypoimmunogenic cells |
WO2023288281A2 (en) | 2021-07-15 | 2023-01-19 | Fred Hutchinson Cancer Center | Chimeric polypeptides |
AR126622A1 (es) | 2021-07-30 | 2023-10-25 | Kws Saat Se & Co Kgaa | Plantas con digestibilidad mejorada y haplotipos marcadores |
IL310550A (en) | 2021-08-04 | 2024-03-01 | Univ Colorado Regents | LAT-activating chimeric antigen receptor T cells and methods of using them |
KR20240054423A (ko) | 2021-08-10 | 2024-04-25 | 가미다-셀 리미티드 | 조작된 nk 세포, 이의 생산방법 및 용도 |
IL310691A (en) | 2021-08-11 | 2024-04-01 | Sana Biotechnology Inc | Genetically modified primary cells for allogeneic cell therapy |
AU2022325231A1 (en) | 2021-08-11 | 2024-02-08 | Sana Biotechnology, Inc. | Genetically modified cells for allogeneic cell therapy to reduce complement-mediated inflammatory reactions |
AU2022325955A1 (en) | 2021-08-11 | 2024-02-08 | Sana Biotechnology, Inc. | Genetically modified cells for allogeneic cell therapy to reduce instant blood mediated inflammatory reactions |
EP4384544A1 (en) | 2021-08-11 | 2024-06-19 | Sana Biotechnology, Inc. | Genetically modified cells for allogeneic cell therapy |
AU2022327174A1 (en) | 2021-08-11 | 2024-02-15 | Sana Biotechnology, Inc. | Inducible systems for altering gene expression in hypoimmunogenic cells |
GB202112865D0 (en) | 2021-09-09 | 2021-10-27 | Tropic Biosciences Uk Ltd | Resistance to black sigatoka disease in banana |
GB202112866D0 (en) | 2021-09-09 | 2021-10-27 | Tropic Biosciences Uk Ltd | Resistance to fusarium wilt in a banana |
AU2022356378A1 (en) | 2021-09-30 | 2024-05-02 | Two Blades Foundation | Plant disease resistance genes against stem rust and methods of use |
WO2023064872A1 (en) | 2021-10-14 | 2023-04-20 | Precision Biosciences, Inc. | Combinations of anti-bcma car t cells and gamma secretase inhibitors |
AU2022371430A1 (en) | 2021-10-19 | 2024-05-30 | Precision Biosciences, Inc. | Gene editing methods for treating alpha-1 antitrypsin (aat) deficiency |
AU2022368911A1 (en) | 2021-10-19 | 2024-05-30 | Precision Biosciences, Inc. | Gene editing methods for treating alpha-1 antitrypsin (aat) deficiency |
WO2023069790A1 (en) | 2021-10-22 | 2023-04-27 | Sana Biotechnology, Inc. | Methods of engineering allogeneic t cells with a transgene in a tcr locus and associated compositions and methods |
CA3237482A1 (en) | 2021-11-03 | 2023-05-11 | The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone | Precise genome editing using retrons |
WO2023081767A1 (en) | 2021-11-05 | 2023-05-11 | Precision Biosciences, Inc. | Methods for immunotherapy |
US11753677B2 (en) | 2021-11-10 | 2023-09-12 | Encodia, Inc. | Methods for barcoding macromolecules in individual cells |
WO2023087019A2 (en) | 2021-11-15 | 2023-05-19 | The Trustees Of The University Of Pennsylvania | Compositions for drg-specific reduction of transgene expression |
WO2023091910A1 (en) | 2021-11-16 | 2023-05-25 | Precision Biosciences, Inc. | Methods for cancer immunotherapy |
WO2023093862A1 (en) | 2021-11-26 | 2023-06-01 | Epigenic Therapeutics Inc. | Method of modulating pcsk9 and uses thereof |
WO2023102550A2 (en) | 2021-12-03 | 2023-06-08 | The Broad Institute, Inc. | Compositions and methods for efficient in vivo delivery |
WO2023111130A1 (en) | 2021-12-17 | 2023-06-22 | Tropic Biosciences UK Limited | Modified agrobacteria for editing plants |
WO2023122722A1 (en) | 2021-12-22 | 2023-06-29 | Sangamo Therapeutics, Inc. | Novel zinc finger fusion proteins for nucleobase editing |
WO2023122337A1 (en) | 2021-12-23 | 2023-06-29 | Sana Biotechnology, Inc. | Chimeric antigen receptor (car) t cells for treating autoimmune disease and associated methods |
WO2023133525A1 (en) | 2022-01-07 | 2023-07-13 | Precision Biosciences, Inc. | Optimized polynucleotides for protein expression |
WO2023141602A2 (en) | 2022-01-21 | 2023-07-27 | Renagade Therapeutics Management Inc. | Engineered retrons and methods of use |
WO2023148478A1 (en) | 2022-02-03 | 2023-08-10 | Nicoventures Trading Limited | Method of modulating alkaloid content in tobacco plants |
WO2023148476A1 (en) | 2022-02-03 | 2023-08-10 | Nicoventures Trading Limited | Method of modulating alkaloid content in tobacco plants |
WO2023148475A1 (en) | 2022-02-04 | 2023-08-10 | Nicoventures Trading Limited | Method of modulating alkaloid content in tobacco plants |
WO2023154578A1 (en) | 2022-02-14 | 2023-08-17 | Sana Biotechnology, Inc. | Methods of treating patients exhibiting a prior failed therapy with hypoimmunogenic cells |
WO2023158836A1 (en) | 2022-02-17 | 2023-08-24 | Sana Biotechnology, Inc. | Engineered cd47 proteins and uses thereof |
WO2023161178A1 (en) | 2022-02-22 | 2023-08-31 | Ecole Polytechnique Federale De Lausanne (Epfl) | Cgas super-enzymes for cancer immunotherapy |
WO2023173123A1 (en) | 2022-03-11 | 2023-09-14 | Sana Biotechnology, Inc. | Genetically modified cells and compositions and uses thereof |
WO2023196818A1 (en) | 2022-04-04 | 2023-10-12 | The Regents Of The University Of California | Genetic complementation compositions and methods |
GB202205149D0 (en) | 2022-04-07 | 2022-05-25 | Nicoventures Trading Ltd | Method |
GB202205148D0 (en) | 2022-04-07 | 2022-05-25 | Nicoventures Trading Ltd | Method |
GB202205562D0 (en) | 2022-04-14 | 2022-06-01 | Nicoventures Trading Ltd | Method |
GB202205561D0 (en) | 2022-04-14 | 2022-06-01 | Nicoventures Trading Ltd | Method |
GB202206109D0 (en) | 2022-04-27 | 2022-06-08 | Nicoventures Trading Ltd | Method |
GB202206107D0 (en) | 2022-04-27 | 2022-06-08 | Nicoventures Trading Ltd | Method |
WO2023215725A1 (en) | 2022-05-02 | 2023-11-09 | Fred Hutchinson Cancer Center | Compositions and methods for cellular immunotherapy |
WO2023215498A2 (en) | 2022-05-05 | 2023-11-09 | Modernatx, Inc. | Compositions and methods for cd28 antagonism |
WO2023220035A1 (en) | 2022-05-09 | 2023-11-16 | Synteny Therapeutics, Inc. | Erythroparvovirus compositions and methods for gene therapy |
WO2023220040A1 (en) | 2022-05-09 | 2023-11-16 | Synteny Therapeutics, Inc. | Erythroparvovirus with a modified capsid for gene therapy |
WO2023220043A1 (en) | 2022-05-09 | 2023-11-16 | Synteny Therapeutics, Inc. | Erythroparvovirus with a modified genome for gene therapy |
EP4278891A1 (en) | 2022-05-20 | 2023-11-22 | KWS SAAT SE & Co. KGaA | Clubroot resistance and markers in brassica |
WO2024015966A2 (en) | 2022-07-15 | 2024-01-18 | The Trustees Of The University Of Pennsylvania | Recombinant aav having aav clade d and clade e capsids and compositions containing same |
WO2024040222A1 (en) | 2022-08-19 | 2024-02-22 | Generation Bio Co. | Cleavable closed-ended dna (cedna) and methods of use thereof |
WO2024044723A1 (en) | 2022-08-25 | 2024-02-29 | Renagade Therapeutics Management Inc. | Engineered retrons and methods of use |
WO2024042199A1 (en) | 2022-08-26 | 2024-02-29 | KWS SAAT SE & Co. KGaA | Use of paired genes in hybrid breeding |
WO2024056902A2 (en) | 2022-09-16 | 2024-03-21 | Christopher Shaw | Compositions and methods for treating neurological diseases |
WO2024079157A1 (en) | 2022-10-11 | 2024-04-18 | KWS SAAT SE & Co. KGaA | Virus and insect resistance and markers in barley |
WO2024097639A1 (en) | 2022-10-31 | 2024-05-10 | Modernatx, Inc. | Hsa-binding antibodies and binding proteins and uses thereof |
WO2024102277A2 (en) | 2022-11-07 | 2024-05-16 | Syngenta Crop Protection Ag | Genes altering soy plant flowering time and/or maturation and uses thereof |
WO2024118866A1 (en) | 2022-12-01 | 2024-06-06 | Modernatx, Inc. | Gpc3-specific antibodies, binding domains, and related proteins and uses thereof |
WO2024124044A1 (en) | 2022-12-07 | 2024-06-13 | The Brigham And Women’S Hospital, Inc. | Compositions and methods targeting sat1 for enhancing anti¬ tumor immunity during tumor progression |
WO2024126696A1 (en) | 2022-12-14 | 2024-06-20 | King's College London | Compositions and methods for treating neurological diseases |
GB202305021D0 (en) | 2023-04-04 | 2023-05-17 | Tropic Biosciences Uk Ltd | Methods for generating breaks in a genome |
Family Cites Families (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0264166B1 (en) | 1986-04-09 | 1996-08-21 | Genzyme Corporation | Transgenic animals secreting desired proteins into milk |
US4873316A (en) | 1987-06-23 | 1989-10-10 | Biogen, Inc. | Isolation of exogenous recombinant proteins from the milk of transgenic mammals |
US6156304A (en) | 1990-12-20 | 2000-12-05 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Gene transfer for studying and treating a connective tissue of a mammalian host |
US5384253A (en) | 1990-12-28 | 1995-01-24 | Dekalb Genetics Corporation | Genetic transformation of maize cells by electroporation of cells pretreated with pectin degrading enzymes |
WO1993004169A1 (en) | 1991-08-20 | 1993-03-04 | Genpharm International, Inc. | Gene targeting in animal cells using isogenic dna constructs |
US5792640A (en) | 1992-04-03 | 1998-08-11 | The Johns Hopkins University | General method to clone hybrid restriction endonucleases using lig gene |
US5436150A (en) | 1992-04-03 | 1995-07-25 | The Johns Hopkins University | Functional domains in flavobacterium okeanokoities (foki) restriction endonuclease |
US6395959B1 (en) | 1992-05-05 | 2002-05-28 | Institut Pasteur | Nucleotide sequence encoding the enzyme I SceI and the use thereof |
US5792632A (en) | 1992-05-05 | 1998-08-11 | Institut Pasteur | Nucleotide sequence encoding the enzyme I-SceI and the uses thereof |
US5474896A (en) | 1992-05-05 | 1995-12-12 | Institut Pasteur | Nucleotide sequence encoding the enzyme I-SceI and the uses thereof |
US5997861A (en) | 1994-10-31 | 1999-12-07 | Burstein Laboratories, Inc. | Antiviral supramolecules containing target-binding molecules and therapeutic molecules bound to spectrin |
US5830729A (en) | 1996-04-18 | 1998-11-03 | Institut Pasteur | I Sce I-induced gene replacement and gene conversion in embryonic stem cells |
US6265196B1 (en) | 1996-05-07 | 2001-07-24 | Johns Hopkins University | Methods for inactivating target DNA and for detecting conformational change in a nucleic acid |
US6056973A (en) | 1996-10-11 | 2000-05-02 | Sequus Pharmaceuticals, Inc. | Therapeutic liposome composition and method of preparation |
US6060082A (en) | 1997-04-18 | 2000-05-09 | Massachusetts Institute Of Technology | Polymerized liposomes targeted to M cells and useful for oral or mucosal drug delivery |
US7041814B1 (en) | 1998-02-18 | 2006-05-09 | Genome Therapeutics Corporation | Nucleic acid and amino acid sequences relating to Enterobacter cloacae for diagnostics and therapeutics |
CA2361191A1 (en) | 1999-02-03 | 2000-08-10 | The Children's Medical Center Corporation | Gene repair involving the induction of double-stranded dna cleavage at a chromosomal target site |
AU2982300A (en) | 1999-02-03 | 2000-08-25 | Children's Medical Center Corporation | Gene repair involving (in vivo) excision of targeting dna |
US6794136B1 (en) | 2000-11-20 | 2004-09-21 | Sangamo Biosciences, Inc. | Iterative optimization in the design of binding proteins |
US6511676B1 (en) | 1999-11-05 | 2003-01-28 | Teni Boulikas | Therapy for human cancers using cisplatin and other drugs or genes encapsulated into liposomes |
US6593308B2 (en) | 1999-12-03 | 2003-07-15 | The Regents Of The University Of California | Targeted drug delivery with a hyaluronan ligand |
US6988041B2 (en) | 2000-01-31 | 2006-01-17 | Pharmacia & Upjohn Company | Crystallization and structure determination of Staphylococcus aureus NAD synthetase |
DE10131786A1 (de) | 2001-07-04 | 2003-01-16 | Sungene Gmbh & Co Kgaa | Rekombinationssysteme und Verfahren zum Entfernen von Nukleinsäuresequenzen aus dem Genom eukaryotischer Organismen |
AU2002319696B2 (en) | 2001-07-27 | 2007-11-01 | The Government Of The United States Of America As Represented By The Secretary Of Health And Human Services | Systems for in vivo site-directed mutagenesis using oligonucleotides |
BRPI0307383B1 (pt) | 2002-01-23 | 2019-12-31 | The Univ Of Utah Research Foundation | método de recombinação genética direcionada em célula de planta hospedeira |
DE60316124T3 (de) | 2002-03-15 | 2018-03-22 | Cellectis | Hybride and einzelkettige meganukleasen und deren anwendungen |
DE10226316B4 (de) * | 2002-06-10 | 2004-10-28 | Siemens Ag | Verfahren zum Einrichten eines Zusatzdientes in einem Mobilfunknetz |
WO2004037977A2 (en) | 2002-09-05 | 2004-05-06 | California Institute Of Thechnology | Use of chimeric nucleases to stimulate gene targeting |
AU2003290518A1 (en) | 2002-09-06 | 2004-04-23 | Fred Hutchinson Cancer Research Center | Methods and compositions concerning designed highly-specific nucleic acid binding proteins |
US7285699B2 (en) | 2002-10-07 | 2007-10-23 | Stowers Institute For Medical Research | Ends-out gene targeting method |
US20030175968A1 (en) | 2002-10-30 | 2003-09-18 | Golic Kent G. | Gene targeting method |
AU2004208031B2 (en) * | 2003-01-28 | 2009-10-08 | Cellectis | Use of meganucleases for inducing homologous recombination ex vivo and in toto in vertebrate somatic tissues and application thereof. |
US7888121B2 (en) | 2003-08-08 | 2011-02-15 | Sangamo Biosciences, Inc. | Methods and compositions for targeted cleavage and recombination |
PL1689870T3 (pl) | 2003-11-18 | 2009-06-30 | Bayer Cropscience Nv | Ulepszona docelowa insercja DNA w roślinach |
EP1591521A1 (en) | 2004-04-30 | 2005-11-02 | Cellectis | I-Dmo I derivatives with enhanced activity at 37 degrees C and use thereof |
US20110158974A1 (en) | 2005-03-15 | 2011-06-30 | Cellectis | Heterodimeric Meganucleases and Use Thereof |
WO2007034262A1 (en) | 2005-09-19 | 2007-03-29 | Cellectis | Heterodimeric meganucleases and use thereof |
WO2006097784A1 (en) * | 2005-03-15 | 2006-09-21 | Cellectis | I-crei meganuclease variants with modified specificity, method of preparation and uses thereof |
WO2007049095A1 (en) | 2005-10-25 | 2007-05-03 | Cellectis | Laglidadg homing endonuclease variants having mutations in two functional subdomains and use thereof |
WO2007060495A1 (en) | 2005-10-25 | 2007-05-31 | Cellectis | I-crei homing endonuclease variants having novel cleavage specificity and use thereof |
WO2007093836A1 (en) | 2006-02-13 | 2007-08-23 | Cellectis | Meganuclease variants cleaving a dna target sequence from a xp gene and uses thereof |
WO2008010009A1 (en) | 2006-07-18 | 2008-01-24 | Cellectis | Meganuclease variants cleaving a dna target sequence from a rag gene and uses thereof |
-
2006
- 2006-10-18 JP JP2008536805A patent/JP5937292B2/ja active Active
- 2006-10-18 EP EP10191888A patent/EP2357226B1/en active Active
- 2006-10-18 ES ES10191904.1T patent/ES2533370T3/es active Active
- 2006-10-18 WO PCT/US2006/040919 patent/WO2007047859A2/en active Application Filing
- 2006-10-18 EP EP13164564.0A patent/EP2650365B1/en active Active
- 2006-10-18 DK DK12162075.1T patent/DK2484758T3/da active
- 2006-10-18 DK DK13164623.4T patent/DK2662442T3/da active
- 2006-10-18 CA CA2626262A patent/CA2626262C/en active Active
- 2006-10-18 EP EP13164623.4A patent/EP2662442B1/en active Active
- 2006-10-18 CA CA3055968A patent/CA3055968A1/en active Pending
- 2006-10-18 ES ES17161899T patent/ES2829549T3/es active Active
- 2006-10-18 ES ES13164585.5T patent/ES2626025T3/es active Active
- 2006-10-18 EP EP10191904.1A patent/EP2360244B1/en active Active
- 2006-10-18 AT AT10191888T patent/ATE549401T1/de active
- 2006-10-18 ES ES13164628.3T patent/ES2582091T3/es active Active
- 2006-10-18 ES ES12162075.1T patent/ES2440801T3/es active Active
- 2006-10-18 DK DK06826293.0T patent/DK1945762T3/da active
- 2006-10-18 EP EP10191885A patent/EP2327774A3/en not_active Withdrawn
- 2006-10-18 CA CA2891996A patent/CA2891996A1/en active Pending
- 2006-10-18 EP EP20190719.3A patent/EP3795682A3/en active Pending
- 2006-10-18 DK DK10191904T patent/DK2360244T3/da active
- 2006-10-18 DK DK13164585.5T patent/DK2650366T3/da active
- 2006-10-18 EP EP13164628.3A patent/EP2628794B1/en active Active
- 2006-10-18 US US11/583,368 patent/US8021867B2/en active Active
- 2006-10-18 EP EP13164585.5A patent/EP2650366B1/en active Active
- 2006-10-18 DK DK17161899.4T patent/DK3246403T3/da active
- 2006-10-18 DK DK10191888.6T patent/DK2357226T3/da active
- 2006-10-18 ES ES06826293T patent/ES2425022T3/es active Active
- 2006-10-18 EP EP10191923A patent/EP2368981A3/en not_active Withdrawn
- 2006-10-18 EP EP17161899.4A patent/EP3246403B1/en active Active
- 2006-10-18 ES ES13164564.0T patent/ES2602184T3/es active Active
- 2006-10-18 EP EP12162075.1A patent/EP2484758B1/en active Active
- 2006-10-18 DK DK13164564.0T patent/DK2650365T3/da active
- 2006-10-18 EP EP06826293.0A patent/EP1945762B1/en active Active
- 2006-10-18 DK DK13164628.3T patent/DK2628794T3/da active
- 2006-10-18 ES ES13164623.4T patent/ES2539616T3/es active Active
- 2006-10-18 AU AU2006304668A patent/AU2006304668B2/en active Active
- 2006-10-18 EP EP10191915A patent/EP2341135A3/en not_active Withdrawn
- 2006-10-18 ES ES10191888T patent/ES2384440T3/es active Active
-
2011
- 2011-09-01 US US13/223,852 patent/US20120030783A1/en not_active Abandoned
- 2011-09-26 US US13/245,596 patent/US8119381B2/en active Active
- 2011-09-26 US US13/245,650 patent/US8143015B2/en active Active
- 2011-09-26 US US13/245,607 patent/US8119361B2/en active Active
- 2011-09-27 US US13/246,380 patent/US8124369B2/en active Active
- 2011-09-27 US US13/246,346 patent/US8163514B2/en active Active
- 2011-09-27 US US13/246,263 patent/US8143016B2/en active Active
- 2011-09-27 US US13/246,355 patent/US8133697B2/en active Active
- 2011-09-27 US US13/246,270 patent/US8129134B2/en active Active
- 2011-09-27 US US13/246,376 patent/US8148098B2/en active Active
- 2011-12-01 US US13/308,666 patent/US20120070877A1/en not_active Abandoned
-
2012
- 2012-04-26 US US13/457,041 patent/US8304222B1/en active Active
- 2012-05-14 JP JP2012110691A patent/JP6148437B2/ja active Active
- 2012-06-01 JP JP2012125663A patent/JP6050611B2/ja active Active
- 2012-06-25 US US13/532,190 patent/US8377674B2/en active Active
-
2013
- 2013-04-11 US US13/861,106 patent/US20130227720A1/en not_active Abandoned
-
2014
- 2014-08-19 US US14/463,059 patent/US20150135345A1/en not_active Abandoned
-
2016
- 2016-08-30 JP JP2016167826A patent/JP2017048179A/ja active Pending
-
2017
- 2017-03-11 US US15/456,518 patent/US20170335299A1/en not_active Abandoned
- 2017-09-15 JP JP2017177739A patent/JP2018039808A/ja active Pending
-
2018
- 2018-12-28 JP JP2018246447A patent/JP2019077698A/ja active Pending
-
2019
- 2019-09-13 US US16/570,623 patent/US20200109383A1/en not_active Abandoned
-
2020
- 2020-11-27 JP JP2020196767A patent/JP2021054830A/ja active Pending
-
2021
- 2021-03-23 US US17/210,219 patent/US20210284980A1/en not_active Abandoned
-
2022
- 2022-02-08 JP JP2022017853A patent/JP2022070928A/ja active Pending
-
2023
- 2023-09-13 JP JP2023148314A patent/JP2024001024A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK2650366T3 (da) | Rationelt konstruerede meganucleaser med ændret sekvensspecificitet og DNA-bindingsaffinitet | |
US20110033935A1 (en) | Rationally-designed meganucleases with recognition sequences found in dnase hypersensitive regions of the human genome | |
US20240228994A9 (en) | Rationally-designed meganucleases with altered sequence specificity and dna-binding affinity |